Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02690818 · ClinicalTrials.gov registry record · NA
Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging
A NA study, sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02690818: Completed NA study, sponsored by University of Arizona.
NCT02690818 is a NA study that has completed, run by University of Arizona. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02690818, a NA study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to determine whether regularly scheduled medication reminder text messages (SMS) are effective in increasing latent tuberculosis infection (LTBI) treatment completion.
Primary Outcome
How many approached by clinic, how many referred, how many study eligible, how many consented; why ineligible or refused; how long to recruit each patient
Interventions
- BEHAVIORAL Regularly scheduled LTBI medication reminder text messages
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-09-26 |
| Phase | NA |
What the finished NCT02690818 record still lists
NCT02690818 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Regularly scheduled LTBI medication reminder text messages is the first listed.
NCT02690818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02690818 about?
NCT02690818 is a clinical study titled "Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging". The purpose of this pilot study is to determine whether regularly scheduled medication reminder text messages (SMS) are effective in increasing latent tuberculosis infection (LTBI) treatment completion.
What is the current status of trial NCT02690818?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-04. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT02690818?
The interventions under investigation include: Regularly scheduled LTBI medication reminder text messages (BEHAVIORAL).
Who is sponsoring clinical trial NCT02690818?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02690818's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia